Zydus Lifesciences

Certificate under regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended on December 31, 2025.

07 Jan, 2026 | 03:09pm • Source: BSE

Dissolution of a wholly owned subsidiary

02 Jan, 2026 | 02:36pm • Source: BSE

Receipt of demand Order-In-Original from Assistant Commissioner of State Tax, Gujarat

30 Dec, 2025 | 06:29pm • Source: BSE

Newspaper publication regarding opening of a special window for re-lodgement of transfer requests for physical shares in accordance with SEBI Circular dated July 2, 2025...

27 Dec, 2025 | 02:51pm • Source: BSE

Intimation of ESG Rating

26 Dec, 2025 | 07:13pm • Source: BSE

Intimation of trading window closure

26 Dec, 2025 | 06:52pm • Source: BSE

Newspaper publication of notice of loss of share certificate of the Company, published in the Financial Express English and Gujarati editions, both on December 26,...

26 Dec, 2025 | 12:46pm • Source: BSE

Update on acquisition of API business

24 Dec, 2025 | 05:57pm • Source: BSE

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 19, 2025, titled "Zydus Lifesciences Limited signs an exclusive agreement with Myriad...

19 Dec, 2025 | 09:57am • Source: NSE

Zydus Lifesciences Limited signs an exclusive agreement with Myriad Genetics of US to launch cancer-risk assessment diagnostic tests in India.

19 Dec, 2025 | 09:52am • Source: BSE

Sentynl Therapeutics Announces FDA Acceptance of CUTX-101 NDA Resubmission.

15 Dec, 2025 | 06:30pm • Source: BSE

Zydus launches biosimilar Denosumab 120 mg SC - protecting bone health in cancer patients.

10 Dec, 2025 | 10:18am • Source: BSE

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 10, 2025, titled "Zydus launches biosimilar Denosumab 120 mg SC protecting bone...

10 Dec, 2025 | 10:16am • Source: NSE

Zydus and Formycon enter into an Exclusive Partnership for the Licensing and Supply of Biosimilar to Keytruda (Pembrolizumab), in US and Canada.

09 Dec, 2025 | 05:31pm • Source: BSE

Zydus receives EIR for the injectable facility located at Jarod.

04 Dec, 2025 | 12:47pm • Source: BSE

Zydus receives tentative approval from USFDA for Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg.

27 Nov, 2025 | 04:31pm • Source: BSE

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 26, 2025, titled "Zydus and RK Pharma enter into an exclusive licensing...

26 Nov, 2025 | 12:44pm • Source: NSE

Zydus and RK Pharma enter into an exclusive licensing and commercialization agreement for a novel 505(b)(2) product of supportive oncology treatment for the USA market.

26 Nov, 2025 | 12:27pm • Source: BSE

Zydus receives final approval from USFDA for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg, and 240 mg.

25 Nov, 2025 | 03:58pm • Source: BSE

Corporate presentation

25 Nov, 2025 | 11:19am • Source: BSE